Effector mechanisms of therapeutic antibodies against ErbB receptors.

摘要: ErbB1 and ErbB2 constitute validated target antigens for tumor therapy — as documented by the approval of antibodies tyrosine kinase inhibitors (TKIs) against both antigens. However, their complex biology in development tumorigenesis poses significant challenges on optimization this targeted approach. Crystallographic studies have significantly improved concepts about structure/function relationships these receptors, may assist improving efficacy ErbB-directed therapy over following years. Here, we will review recent advances implications therapies. Although focus mechanisms action ErbB therapeutic antibodies, also briefly discuss TKIs.